CNCR
$9.02
Range Cancer Therapeutics ETF
Fund Family: ETF Series Solutions
1 Month
+0.00%
YTD
-37.92%
1 Year
-37.92%
3 Year
-40.77%
Top 10 Holdings (26.9% of portfolio)
| Rank | Company | Ticker | Sector | Weight |
|---|---|---|---|---|
| 1 | Recursion Pharmaceuticals Inc | RXRX | Professional, Scientific, and Technical Services | 4.01% |
| 2 | Precigen Inc | PGEN | Professional, Scientific, and Technical Services | 3.05% |
| 3 | Compass Therapeutics Inc | CMPX | Professional, Scientific, and Technical Services | 2.99% |
| 4 | Genelux Corp | GNLX | Unknown | 2.90% |
| 5 | SpringWorks Therapeutics Inc | 85205L107 | Unknown | 2.86% |
| 6 | Exelixis, Inc. | EX9 | Unknown | 2.48% |
| 7 | Ginkgo Bioworks Holdings Inc | DNA | Manufacturing | 2.33% |
| 8 | Replimune Group Inc | REPL | Professional, Scientific, and Technical Services | 2.14% |
| 9 | Bristol-Myers Squibb Co | BMY | Manufacturing | 2.10% |
| 10 | Schrodinger Inc/United States | SDGR | Manufacturing | 1.98% |
Fund Information
| Net Assets | $8.93M | Expense Ratio | N/A |
| Total Holdings | 76 | Annual Fee* | N/A |
| Inception Date | N/A | Fund Family | ETF Series Solutions |
*Annual fee per $10,000 invested